
Amrita Journal of Medicine, Journal Year: 2024, Volume and Issue: 20(4), P. 190 - 191
Published: Oct. 1, 2024
Language: Английский
Amrita Journal of Medicine, Journal Year: 2024, Volume and Issue: 20(4), P. 190 - 191
Published: Oct. 1, 2024
Language: Английский
Frontiers in Psychiatry, Journal Year: 2024, Volume and Issue: 15
Published: April 23, 2024
Premenstrual syndrome (PMS) is a common disorder affecting women of reproductive age, with an estimated global prevalence 47.8%, severe symptoms occurring in 3-8%, significantly daily functioning. GABA conductance and changes neurosteroid levels, particularly allopregnanolone, are suspected to play substantial role the disorder’s etiology. In this paper, we provide overview recent reports on etiology recognized therapeutic approaches, encompassing both pharmacological non-pharmacological interventions. Our examination includes studies SSRIs, hormonal agents, neurosteroids, supplementation, roles. We aim determine most favorable treatment regimen by comparing medication effects alternative methods. The PMS crucial for enhancing quality life affected women. Medications used should be individually selected achieve best effect, considering clinical situation patients.
Language: Английский
Citations
14Nature Reviews Endocrinology, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 25, 2024
Language: Английский
Citations
6Endocrinology, Journal Year: 2024, Volume and Issue: 165(9)
Published: July 17, 2024
Risky alcohol use and disorders (AUD) are a rising problem in women, yet major disparity our understanding of what drives consumption women remains. Historically biomedical research has focused on male subjects; however, recent increases reporting females, have highlighted differences between the sexes. Here we review current literature effect gonadal steroid hormones (estrogens, androgens, progestins), neurosteriods, neurobiological factors clinical preclinical studies both Further, briefly discuss how fundamental sex genetics, metabolism, neuroimmune, stress responses may influence intake. Comparing sexes could aid discovery novel therapeutics to treat AUD, implementation treatment options women.
Language: Английский
Citations
4Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)
Published: Sept. 6, 2024
Language: Английский
Citations
4Brain Behavior and Immunity Integrative, Journal Year: 2025, Volume and Issue: unknown, P. 100103 - 100103
Published: Jan. 1, 2025
Language: Английский
Citations
0Journal of Developmental Origins of Health and Disease, Journal Year: 2025, Volume and Issue: 16
Published: Jan. 1, 2025
Abstract Preterm birth exposes the neonate to hypoxic-ischaemic and excitotoxic insults that impair neurodevelopment are magnified by premature loss of placentally supplied, inhibitory neurosteroids. The cerebellum is a neuronally dense brain region, which undergoes critical periods development during late gestation, when preterm births frequently occur. We propose neurosteroid replacement therapy using tiagabine zuranolone will protect against preterm-associated insults. Guinea pig dams received c-section surgery (gestational age (GA) 64) or at term (GA70) with pups administered (2.5 mg/kg/day), (1 mg/kg/day) vehicle (15% β-cyclodextrin) until equivalent (GA70). Behavioural testing was performed corrected postnatal day 8 (PND8) PND41 tissue collection occurring PND42. Neurodevelopmental markers (MBP, OLIG2 NeuN) were assessed within immunohistochemistry, whilst GABAergic glutamatergic pathway expression quantified high throughput RT-PCR. Zuranolone and, lesser extent, able hyperactive behaviour PND8 in males, females, less marked phenotype present neither treatment impacting further. Both treatments improved MBP staining, found restore oligodendrocyte maturation females only. be restored both females. Overall, this study demonstrates neuroprotective attributes zuranolone, thereby demonstrating their potential mitigate long-term neurodevelopmental impairments. Furthermore, sexually dimorphic effects observed suggest future investigations may show increased benefit sex-specific regimes.
Language: Английский
Citations
0The Journal of Steroid Biochemistry and Molecular Biology, Journal Year: 2025, Volume and Issue: 251, P. 106766 - 106766
Published: April 25, 2025
Language: Английский
Citations
0Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)
Published: May 22, 2025
Language: Английский
Citations
0Brain and Behavior, Journal Year: 2024, Volume and Issue: 14(9)
Published: Sept. 1, 2024
Abstract Background Preterm birth is associated with brain injury and long‐term behavioral abnormalities, for which there are limited prevention options. When born preterm, infants prematurely lose placental neurosteroid (allopregnanolone) support. This increases the risk of excitotoxic damage to brain, injury, causing deficits in behavior, myelination, alterations neurotransmitter pathways. We propose that postnatal restoration action through zuranolone therapy will reduce neurological impairments following preterm birth. Methods: Guinea pig dams underwent survival cesarean section surgery deliver pups (GA64) or at term (GA69). Between equivalence age, received vehicle (15% β‐cyclodextrin) allopregnanolone analogue (1 mg/kg/day). Behavioral analysis was performed day (PND) 7 40, before tissue collection PND 42. Immunostaining myelin basic protein (MBP), as well real‐time polymerase chain reaction characterize oligodendrocyte lineage pathways, frontal cortex tissues. Results: Zuranolone treatment prevented hyperactive phenotype preterm‐born offspring, most markedly males. Additionally, preterm‐related reductions MBP were ameliorated. Several mRNA expression dopaminergic, glutamatergic, GABAergic pathways also restored back a control level. Conclusion: first study assess neuroprotective improved outcomes structural changes continued long until least late childhood timepoint. Clinical studies warranted further exploring possibilities this
Language: Английский
Citations
2International Clinical Psychopharmacology, Journal Year: 2024, Volume and Issue: unknown
Published: June 17, 2024
Postpartum depression (PPD) is an increasingly prevalent but still poorly characterized disorder. Causal and modulating factors include hormones fluctuations, such as estrogen, progesterone, allopregnolone, pathways imbalances, oxytocin kynurenine, chronobiological factors, brain imaging alterations. Treatment may differ from the traditional major management, while selective serotonin reuptake inhibitors sertraline are commonly used suggested by guidelines, neurosteroids brexanolone more convenient zuranolone have been recently approved. Newer ganaxolone, valaxanolone, lysaxanolone currently under development, also esketamine psychedelics promising potential treatments. Other somatic treatments including stimulation techniques light therapy showed benefit. PPD therefore understood as, at least partially, independent depressive Specific individualized pharmacological non-pharmacological therapies progressively being introduced in routine clinical practice.
Language: Английский
Citations
1